Iisrael - heebrea - Ministry of Health

salomon,levin & elstein ltd - irinotecan hydrochloride trihydrate 20 mg / 1 ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

Iisrael - heebrea - Ministry of Health

pharmalogic ltd - irinotecan hydrochloride trihydrate 20 mg / 1 ml - concentrate for solution for infusion - irinotecan - irinotecan is indicated for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an astablished 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer.

Iisrael - heebrea - Ministry of Health

megapharm ltd - metronidazole - ג'ל - metronidazole 7.5 mg/g - metronidazole

Iisrael - heebrea - Ministry of Health

sanofi israel ltd - metronidazole - טבליות מצופות פילם - metronidazole 250 mg - metronidazole - metronidazole - trichomonias, acute intestinal amebiasis. infections due to anaerobic bacteria.

Iisrael - heebrea - Ministry of Health

tzamal bio-pharma ltd - oxaliplatin - אבקה להכנת תמיסה לאינפוזיה - oxaliplatin 150 mg/vial - oxaliplatin - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of primary tumor. - treatment on metastatic colateral cancer.

Iisrael - heebrea - Ministry of Health

perrigo israel agencies ltd - oxaliplatin 50 mg - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for:- adjuvant treatment of stage iii (duke’s c) colon cancer after complete resection of primary tumour.-treatment of metastatic colorectal cancer.

Iisrael - heebrea - Ministry of Health

perrigo israel agencies ltd - oxaliplatin 100 mg - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5-fluorouracil (5-fu) and folinic acid (fa) is indicated for:- adjuvant treatment of stage iii (duke’s c) colon cancer after complete resection of primary tumour.-treatment of metastatic colorectal cancer.

Iisrael - heebrea - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

Iisrael - heebrea - Ministry of Health

sanofi - aventis israel ltd - aflibercept 25 mg/ml - concentrate for solution for infusion - zaltrap, in combination with 5-fluorouracil, leucovorin, irinotecan (folfiri), is indicated for adults with metastatic colorectal cancer (mcrc) that is resistant to or has progressed following an oxaliplatin-containing regimen.

Iisrael - heebrea - Ministry of Health

dexcel ltd, israel - trastuzumab - trastuzumab 420 mg/vial - trastuzumab